Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489537 | 0.84 | CYP19A1 (0.47) | MAOBCYP19A1 | |
| SCHEMBL10975981 | 0.83 | MAOB (0.49) | MAOBCYP19A1KDM4E | |
| SCHEMBL8402135 | 0.77 | SLC6A2 (0.41) | MAOBCYP19A1 | |
| SCHEMBL31598939 | 0.77 | SLC6A2 (0.41) | MAOBCYP19A1 | |
| SCHEMBL7324722 | 0.77 | VHL (0.41) | CYP19A1 | |
| SCHEMBL4867739 | 0.77 | CYP3A4 (0.40) | CYP3A4CYP17A1CYP11B2CYP11B1KDM4E | |
| SCHEMBL4867731 | 0.77 | CYP3A4 (0.40) | CYP3A4CYP17A1CYP11B2CYP11B1KDM4E | |
| SCHEMBL27527067 | 0.77 | ACHE (0.47) | MAOB | |
| SCHEMBL5709369 | 0.76 | CYP3A4 (0.61) | CYP3A4CYP17A1CYP11B2CYP11B1 | |
| SCHEMBL10983553 | 0.75 | KDM4E (0.55) | MAOBCYP19A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | CYP3A4 1174/4885CYP17A1 523/4885CYP11B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.